Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators. Saussele S, et al. Among authors: muller mc. Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4. Lancet Oncol. 2018. PMID: 29735299 Clinical Trial.
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.
Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saußele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Müller MC. Lauseker M, et al. Among authors: muller mc. J Cancer Res Clin Oncol. 2014 Nov;140(11):1965-9. doi: 10.1007/s00432-014-1746-8. Epub 2014 Jun 22. J Cancer Res Clin Oncol. 2014. PMID: 24952896
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Ernst T, Gruber FX, Pelz-Ackermann O, Maier J, Pfirrmann M, Müller MC, Mikkola I, Porkka K, Niederwieser D, Hochhaus A, Lange T. Ernst T, et al. Among authors: muller mc. Haematologica. 2009 Sep;94(9):1227-35. doi: 10.3324/haematol.2009.006981. Epub 2009 Jul 16. Haematologica. 2009. PMID: 19608684 Free PMC article. Clinical Trial.
Current treatment concepts of CML.
Leitner AA, Hochhaus A, Müller MC. Leitner AA, et al. Among authors: muller mc. Curr Cancer Drug Targets. 2011 Jan;11(1):31-43. doi: 10.2174/156800911793743637. Curr Cancer Drug Targets. 2011. PMID: 21062245 Review.
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S. Hehlmann R, et al. Among authors: muller mc. J Clin Oncol. 2011 Apr 20;29(12):1634-42. doi: 10.1200/JCO.2010.32.0598. Epub 2011 Mar 21. J Clin Oncol. 2011. PMID: 21422420 Clinical Trial.
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group. Fabarius A, et al. Among authors: muller mc. Blood. 2011 Dec 22;118(26):6760-8. doi: 10.1182/blood-2011-08-373902. Epub 2011 Oct 28. Blood. 2011. PMID: 22039253 Free article.
BCR-ABL mutations in chronic myeloid leukemia.
Ernst T, La Rosée P, Müller MC, Hochhaus A. Ernst T, et al. Among authors: muller mc. Hematol Oncol Clin North Am. 2011 Oct;25(5):997-1008, v-vi. doi: 10.1016/j.hoc.2011.09.005. Hematol Oncol Clin North Am. 2011. PMID: 22054731 Review.
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.
Lange T, Ernst T, Gruber FX, Maier J, Cross M, Müller MC, Niederwieser D, Hochhaus A, Pfirrmann M. Lange T, et al. Among authors: muller mc. Haematologica. 2013 May;98(5):714-7. doi: 10.3324/haematol.2012.068890. Epub 2012 Oct 12. Haematologica. 2013. PMID: 23065514 Free PMC article.
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.
Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, Hehlmann R; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Kalmanti L, et al. Among authors: muller mc. Ann Hematol. 2014 Jan;93(1):71-80. doi: 10.1007/s00277-013-1937-4. Epub 2013 Oct 27. Ann Hematol. 2014. PMID: 24162333 Free PMC article.
325 results